NCT00041535View on ClinicalTrials.gov

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 5, 2002

Study Completion Date

March 21, 2007

Conditions
Gaucher Disease
Interventions
DRUG

OGT 918

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Unknown

Institute of Child Health, London

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00041535 - OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease | Biotech Hunter | Biotech Hunter